LY2452473 + tadalafil + placebo (tadalafil) + placebo (LY2452473)

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Erectile Dysfunction

Conditions

Erectile Dysfunction

Trial Timeline

Oct 1, 2010 → Nov 1, 2011

NCT ID

NCT01160289

About LY2452473 + tadalafil + placebo (tadalafil) + placebo (LY2452473)

LY2452473 + tadalafil + placebo (tadalafil) + placebo (LY2452473) is a phase 2 stage product being developed by Eli Lilly for Erectile Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT01160289. Target conditions include Erectile Dysfunction.

What happened to similar drugs?

11 of 20 similar drugs in Erectile Dysfunction were approved

Approved (11) Terminated (0) Active (9)

🔄tadalafil + placeboEli LillyPhase 3

✅Tacrolimus + PlaceboAstellas PharmaApproved

🔄tadalafil + placeboEli LillyPhase 3

🔄tadalafilEli LillyPhase 3

✅TadalafilEli LillyApproved

✅tadalafil + placeboEli LillyApproved

✅Tadalafil + Sildenafil CitrateEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01160289	Phase 2	Completed	Oct 1, 2010	Nov 1, 2011	Erectile Dysfunction

Competing Products

20 competing products in Erectile Dysfunction

See all competitors

Product	Company	Stage	Hype Score
tadalafil + placebo	Eli Lilly	Phase 3	40
YHD1023 + YHD1023 + YHD1023 + Cialis + Placebo	Yuhan	Phase 2	35
Tacrolimus + Placebo	Astellas Pharma	Approved	43
Mirabegron	Astellas Pharma	Phase 1/2	32
LY2452473 + Tadalafil + LY900010	Eli Lilly	Phase 1	29
tadalafil + placebo	Eli Lilly	Phase 3	40
tadalafil	Eli Lilly	Phase 3	40
Tadalafil	Eli Lilly	Approved	43
tadalafil + placebo	Eli Lilly	Approved	43
Tadalafil + Sildenafil Citrate	Eli Lilly	Approved	43
Tadalafil + Placebo	Eli Lilly	Phase 3	40
Placebo + Tadalafil	Eli Lilly	Approved	43
Tadalafil + Placebo	Eli Lilly	Approved	43
tadalafil	Eli Lilly	Approved	43
Tadalafil + Sildenafil	Eli Lilly	Approved	43
tadalafil once a day [T(OaD)] + sildenafil citrate as needed [S(PRN)] + tadalafil as needed [T(PRN)]	Eli Lilly	Phase 3	40
Tadalafil + Placebo	Eli Lilly	Approved	43
Dapoxetine	Johnson & Johnson	Phase 3	40
dapoxetine	Johnson & Johnson	Phase 3	40
Placebo + Dapoxetine + PDE5I (phosphodiesterase-5 inhibitor)	Johnson & Johnson	Phase 3	40